Hypoalbuminemia and Posaconazole Therapeutic Drug Monitoring

被引：0
作者：
Nix, David E. [1 ]
Al-Obaidi, Mohanad [2 ]
Zangeneh, Tirdad [2 ]
机构：
[1] Univ Arizona, Pharm Practice & Sci, R Ken Coit Coll Pharm, Tucson, AZ USA
[2] Univ Arizona, Div Infect Dis, Tucson, AZ USA
来源：
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 08期
关键词：
INVASIVE PULMONARY ASPERGILLOSIS; PHARMACODYNAMICS; TRIAZOLE; MODEL;
D O I：
10.1093/ofid/ofae452
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：3
相关论文
共 14 条
  • [1] In vivo pharmacodynamics of a new triazole, ravulconazole, in a murine candidiasis model
    Andes, D
    Marchillo, K
    Stamstad, T
    Conklin, R
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) : 1193 - 1199
  • [2] Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
    Andes, D
    Marchillo, K
    Conklin, R
    Krishna, G
    Ezzet, F
    Cacciapuoti, A
    Loebenberg, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) : 137 - 142
  • [3] Hypoalbuminemia and Pharmacokinetics: When the Misunderstanding of a Fundamental Concept Leads to Repeated Errors over Decades
    Gandia, Peggy
    Decheiver, Sarah
    Picard, Manon
    Guilhaumou, Romain
    Baklouti, Sarah
    Concordet, Didier
    [J]. ANTIBIOTICS-BASEL, 2023, 12 (03):
  • [4] Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy
    Gastine, Silke
    Hope, William
    Hempel, Georg
    Petraitiene, Ruta
    Petraitis, Vidmantas
    Mickiene, Diana
    Bacher, John
    Walsh, Thomas J.
    Groll, Andreas H.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (02)
  • [5] Hadley G., 2024, Open Forum Infect Dis, V11, pofa
  • [6] Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy
    Howard, Susan J.
    Lestner, Jodi M.
    Sharp, Andrew
    Gregson, Lea
    Goodwin, Joanne
    Slater, Joanne
    Majithiya, Jayesh B.
    Warn, Peter A.
    Hope, William W.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (09): : 1324 - 1332
  • [7] Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis
    Lepak, Alexander J.
    Marchillo, Karen
    VanHecker, Jaimie
    Andes, David R.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (01) : 579 - 585
  • [8] Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis
    Lewis, Russell E.
    Albert, Nathaniel D.
    Kontoyiannis, Dimitrios P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6767 - 6772
  • [9] Posaconazole in Human Serum: a Greater Pharmacodynamic Effect than Predicted by the Non-Protein-Bound Serum Concentration
    Lignell, Anders
    Lowdin, Elisabeth
    Cars, Otto
    Chryssanthou, Erja
    Sjolin, Jan
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (07) : 3099 - 3104
  • [10] Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
    Martson, Anne-Grete
    Veringa, Anette
    van den Heuvel, Edwin R.
    Bakker, Martijn
    Touw, Daan J.
    van der Werf, Tjip S.
    Span, Lambert F. R.
    Alffenaar, Jan-Willem C.
    [J]. MYCOSES, 2019, 62 (08) : 698 - 705
12